# A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.

> **NCT07358156** · PHASE1 · RECRUITING · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 519 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** CKD-706
- **DRUG:** US-Dupixent
- **DRUG:** EU-Dupixent

## Key facts

- **NCT ID:** NCT07358156
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-09
- **Primary completion:** 2026-11-16
- **Final completion:** 2026-11-16
- **Target enrollment:** 519 (ESTIMATED)
- **Last updated:** 2026-01-23

## Collaborators

- Parexel

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07358156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07358156, "A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT07358156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*